PCA3 Responsive Molecular Imaging Enables Spatial Visualization of Prostate Cancer

Imagine a surgeon standing over a patient, trying to remove a cancerous tumor from the prostate. The goal is to cut out every single cancer cell while leaving the healthy tissue untouched, but the human eye cannot see the invisible boundary between the two. In many cases, the cancer cells look identical to the healthy ones under a microscope, and they often hide in the margins of the tissue. To solve this, doctors have long relied on imaging technologies that act like a flashlight, lighting up the tumor so the surgeon can see exactly where to cut. However, current flashlights have limitations: they often glow on healthy tissue by mistake, or they rely on surface markers that some tumors simply do not wear. What if, instead of looking for a surface tag, the surgeon could use a probe that lights up only when it finds a specific genetic message hidden deep inside the cancer cell itself?

This is the challenge researchers at the University Hospital RWTH Aachen and the Forschungszentrum Jülich set out to address. They developed a new type of molecular imaging tool designed to find prostate cancer by listening for a specific genetic whisper inside the cells. The tool is called CaS-DNA, a tiny, engineered strand of DNA that acts like a molecular switch. It is built to recognize PCA3, a long piece of genetic material that is produced in large amounts by prostate cancer cells but is barely present in healthy ones. The researchers wanted to know if they could turn this internal genetic signal into a visible light that a surgeon could see during an operation, offering a way to distinguish cancer from healthy tissue with high precision.

The team began by designing the CaS-DNA probe to be silent until it found its target. In its resting state, the probe is folded into a tight loop, with a light-emitting chemical attached to one end and a light-quenching chemical attached to the other. These two chemicals are so close together that the light is completely suppressed, making the probe invisible. The loop of the DNA is shaped to fit perfectly with the PCA3 genetic message, much like a key fits into a specific lock. When the probe enters a cell and encounters the PCA3 message, it binds to it. This binding forces the DNA to unfold, pulling the light-emitting chemical away from the quenching chemical. Once separated, the light-emitting chemical, known as indocyanine green, begins to glow with a near-infrared signal that can be detected by special cameras.

To test if this mechanism worked, the researchers first looked at it in a simple laboratory setting. They mixed the CaS-DNA probe with the specific genetic target and watched what happened. The probe bound to the target quickly, and the light turned on within minutes. Crucially, when they mixed the probe with a scrambled, non-matching genetic sequence, nothing happened; the light remained off. This proved that the probe was not just reacting to any genetic material, but was specifically tuned to find the PCA3 message. They also checked how stable the probe was under different temperatures and found it remained functional across a wide range of conditions, suggesting it could survive the environment inside a human body.

Next, the researchers moved to living cells to see if the probe could find cancer cells among healthy ones. They grew prostate cancer cells in a dish and compared them to healthy prostate cells and bone cells. The cancer cells, which naturally produce high levels of the PCA3 message, lit up brightly when treated with the probe. The healthy cells, which produce very little or no PCA3, remained dark. The brightness of the light directly matched the amount of PCA3 the cells were producing. In experiments where cancer cells and healthy cells were grown side-by-side, the probe successfully highlighted only the cancer cells, leaving the healthy neighbors in the dark. This demonstrated that the probe could distinguish between the two types of tissue based entirely on their internal genetic activity, rather than relying on surface features that might be missing or inconsistent.

To see if this worked in a living organism, the team used zebrafish larvae, a common model for studying biological processes. They injected cancer cells into the larvae and then introduced the CaS-DNA probe. Over the course of an hour, the probe traveled through the fish and lit up specifically in the areas where the cancer cells had taken hold. The healthy parts of the fish remained dark. This confirmed that the probe could find its target and activate its light signal even within a complex, living system, without being triggered by the surrounding healthy tissue.

The most significant test, however, took place with actual human tissue. The researchers obtained prostate tissue samples that had been surgically removed from patients. They sliced these tissues and treated them with the CaS-DNA probe. After the probe had time to work, they compared the glowing areas to the standard medical maps of where the cancer was located, which were drawn by pathologists after staining the tissue with traditional dyes. The glowing light from the probe matched the cancerous regions with a high degree of accuracy. In fact, the probe covered a similar amount of the tumor area as a widely used clinical standard that targets a different protein called PSMA. This was a major finding because it showed that looking inside the cell for a genetic message could be just as effective as looking for surface proteins, even in the complex environment of a real human tumor.

To understand the details of this match, the researchers used a powerful technique called spatial transcriptomics, which maps out exactly which genes are active in every tiny spot of the tissue. They found that the areas where the CaS-DNA probe glowed matched the areas where the cancer-associated genes were most active. In regions where the cancer cells were mixed with healthy cells, the brightness of the light varied. The probe glowed less brightly in areas where there were fewer cancer cells, suggesting that the intensity of the light could tell the surgeon not just where the cancer is, but how much of it is there. This level of detail is something that many current imaging tools struggle to provide.

The study also looked at the limitations of this new approach. While the probe worked well in the center of the tissue, there were some instances where it lit up slightly at the very edges of the tissue slices. The researchers noted that this might happen because the tissue edges are more fragile and the probe could be reacting to the environment there rather than the cancer itself. They also observed that the probe did not light up every single cancer cell in every sample, which suggests that getting the probe into every cell is a challenge that still needs to be solved. Despite these hurdles, the results showed that the probe could reliably find the cancer in the vast majority of cases.

The researchers concluded that this method offers a new way to visualize prostate cancer. By turning a specific genetic message into a visible light, they created a tool that is highly specific to the cancer cells themselves. This approach does not rely on the cancer cells having a specific surface protein, which is a limitation for some current treatments. Instead, it uses the cell's own internal machinery to signal its presence. The light used in the probe is a chemical already approved for use in humans, which means it could potentially be adapted for use in operating rooms relatively quickly. If this technology can be refined to ensure the probe reaches every cell and stays stable during surgery, it could give surgeons a much clearer view of the tumor, helping them remove all the cancer while saving as much healthy tissue as possible. The work represents a shift from looking at what is on the outside of a cell to listening to what is happening on the inside, offering a new kind of clarity for one of the most common cancers in men.